HJB647 clinical trials
Also written HJB647.
How each study uses HJB647 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HJB647 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HJB647
- 2
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test HJB647.
- Dec 2026A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection FractionPhase 1 · Novartis Pharmaceuticals
- Dec 2026HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With HypertensionPhase 1 · Novartis Pharmaceuticals
- Nov 2027A Safety and Tolerability Study of HJB647 in Adult Participants With Uncontrolled HypertensionPhase 1 · Novartis Pharmaceuticals
Studies
Open first, then newest update. How each study uses HJB647 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Safety and Tolerability Study of HJB647 in Adult Participants With Uncontrolled HypertensionNot yet recruitingPhase 1Novartis PharmaceuticalsNCT07940647Written as HJB647
- A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection FractionRecruitingPhase 1Novartis PharmaceuticalsNCT07465653Written as HJB647 low dose
- HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With HypertensionRecruitingPhase 1Novartis PharmaceuticalsNCT07644364Written as HJB647
What changed recently
From the registry's own updates since Oct 19, 2026.